| Summary: | Jianfei Long,1,* Yu Zhang,1,* Xiang Huang,2 Junwei Ren,2 Ping Zhong,2 Bin Wang1 1Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ping ZhongDepartment of Neurosurgery, Huashan Hospital, Fudan University, No. 12 Middle Wu Lu Mu Qi Road, Shanghai 200040, People’s Republic of ChinaEmail zhp228899@163.comBin WangDepartment of Pharmacy, Huashan Hospital, Fudan University, No. 12 Middle Wu Lu Mu Qi Road, Shanghai 200040, People’s Republic of ChinaTel +86 13916606721Email wangbin@huashan.org.cnAbstract: Vestibular schwannomas (VSs, also known as acoustic neuromas) are benign intracranial tumors commonly managed with observation, surgery, and radiotherapy. There is currently no approved pharmacotherapy for VS patients, which is why we conducted a detailed search of relevant literature from PubMed and Web of Science to explore recent advances and experiences in drug therapy. VSs feature a long course of disease that requires treatment to have minimal long-term side effects. Conventional chemotherapeutic agents are characterized by neurotoxicity or ototoxicity, poor effect on slow-growing tumors, and may induce new mutations in patients who have lost tumor suppressor function, and therefore are unsuitable for treating VSs. Along with the well-investigated molecular pathophysiology of VS and the increasingly accessible technology such as drug repositioning platform, many molecular targeted inhibitors have been identified and shown certain therapeutic effects in preclinical experiments or clinical trials.Keywords: vestibular schwannomas, drug therapy, therapeutic targets, VEGFR inhibitor
|
|---|
